热门资讯> 正文
随着Vyvgart达到自身免疫性脊髓炎的关键试验终点，Lenox取得进展
2026-08-17 16:28
- Shares in Argenx SE (ARGX) jumped on Monday after the European biotech reported the latest large, successful trial for its blockbuster drug Vyvgart.
- The drug helped patients with autoimmune myositis, a disease in which the immune system attacks the muscles and can quickly rob patients of their independence, Argenx said Monday.
- First Phase 3 study to show statistically significant and clinically meaningful improvements in disease activity in IMNM, a subtype with no approved therapy.
- The shares climbed as much as 10%, the most in more than a year on an intraday basis.
More on argenx SE
- argenx SE (ARGX) Forte Biosciences, Inc. - M&A Call - Slideshow
- argenx: Upgrading To Buy, The VYVGART Growth Cycle Has Further To Go
- Forte: 'Hold' On Positive FB102 Vitiligo Treatment Data And argenx Acquisition For $2.2 Billion
- Key deals this week: Ambarella, MarketAxess, argenx SE, TransDigm, and more
- argenx strikes $2.2B deal for Forte Biosciences
推荐文章
美股前瞻 | 盘前狂飙超100%！Moderna癌症治疗迎历史性突破；SK海力士“放大招”：抛出40万亿韩元回购计划！
美银：计入人工智能融资风险后，英伟达仍较自由现金流折价34%至50%
华盛早报 | AI硬件股遭重挫！费城半导体指数跌近5%；美银称英伟达股价或被低估50%；小米Q2营收重回千亿规模
8月19日外盘头条：特朗普称未与伊朗进行任何会谈 苹果调整欧盟应用商店收费 多国长期主权债收益率升至高位
AI交易情绪逆转 苹果“反AI”属性正成股价拖累
全球债券收益率创下数十年来新高：各国为美伊对峙付出代价
美股前瞻 | 警报拉响！美债收益率飙升，纳指期货跌逾1%；存储、半导体齐挫！三倍做多半导体ETF跌超10%
期权交易指南 | 闪迪急弹逾7成、费半重返牛市！该追涨还是止赚？阿里绩前Call单押注升温
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
